

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5,714,586 (equivalent to WO 96/40261)		1998-02-03	American Cyanamid	
	2	7,355,011 (equivalent to WO 03/093320)		2008-04-08	UCB Pharma S.A	
	3	5,714,350		1998-02-03	Co	
	4	5,686,072		1997-11-11	Uhr	
	5	5,693,762		1997-12-02	Queen	
	6	6,183,744 (equivalent to WO 98/56418)		2001-02-06	Immunomedics, Inc.	
	7	5,382,510 (equivalent to WO 92/00311)		1995-01-17	The Trustees of Princeton University	
	8	7,541,034 (equivalent to WO 98/041641)		2009-06-02	The United States of America as represented by the Department of Health and Human Services	
	9	7,012,135 (equivalent to WO 01/94585)		2006-03-14	Celltech Chiroscience Limited	
	10	5,558,864 (equivalent to WO 92/15683)		1996-09-24	Merck Patent Gesellschaft Mit Beschränkter Haftung	
	11	6,180,377 (equivalent to WO 94/29451)		2001-01-30	Celltech Therapeutics Limited	
	12	7,115,723 (equivalent to WO 00/31141)		2006-10-03	Korea Institute of Science & Technology	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

13	5,225,539 (equivalent to EP 0239400)	1993-07-06	Medical Research Council	
14	5,530,101 (equivalent to WO 90/07861)	1996-06-25	Protein Design Labs, Inc.	
15	5,436,265 (equivalent to RU 2131423)	1995-07-25	Merck Frosst Canada, Inc.	
16	7,129,053 (equivalent to WO 01/027612)	2006-10-31	Reiter	
17	7,147,851 (equivalent to WO 98/006248)	2006-12-12	Ponath	
18	6,777,390 (equivalent to WO 99/068031)	2004-08-17	Matthiessen	
19	5,789,554 (equivalent to WO 96/004925)	1998-08-04	Leung	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2006/0073137 (equivalent to WO 91/09967)		2006-04-06	Celltech R&D Limited	
	2	2002/0141990 (equivalent to WO 98/19704)		2002-10-03	SmithKline Beecham Corp	
	3	2007/0172920 (equivalent to JP 10-505231)		2007-02-22	Leung	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

	4	2005/0095238 (equivalent to WO 01/078779)		2005-05-05	Brettman	
--	---	---	--	------------	----------	--

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	96/005306 (equivalent to RU 9710420 A)	WO		1996-02-22	Myriad Genetics, Inc.		
	2	98/56418	WO		1998-12-17	Genetech, Inc.		

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
	1	Benhar et al., "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization," <i>Bioconjugate Chem.</i> , 1994, 5: 321-326. (Abstract only)	<input type="checkbox"/>
	2	Browning et al., "B cells move to centre stage: novel opportunities for autoimmune disease treatment," <i>Nat. Rev. Drug Discov.</i> , 2006, 5: 564-576.	
	3	Carnahan et al., "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties," <i>Clinical Cancer Res.</i> , 2003, 9, suppl.: 3982s-3990s.	
	4	DiJoseph et al., "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22," <i>Cancer Immunol. Immunother.</i> , 2005, 54: 11-24.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

5	DiJoseph et al., "Antibody-targeted chemotherapy with CMC-544, a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies," <i>Blood</i> , 2004, 103: 1807-1814.
6	Leung et al., "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2," <i>Mol. Immunol.</i> , 1995, 32: 1413-1427 (Abstract only)
7	Leung et al., "Effect of V _k framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site," <i>Int. J. Cancer.</i> , 1995, 60: 534-538. (Abstract only)
8	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988, 332:323-327. (Abstract only)
9	Vaughan et al., "Human antibodies by design," <i>Nature Biotech.</i> , 1998, 16: 535-539. (Abstract only)
10	van Rossum et al., "A structure-function study of ligand recognition by CD22 beta," <i>J. Bio. Chem.</i> , 2001, 276: 12967-12973.
11	Verhoeven et al., "Reshaping human antibodies: Grafting an antilysozyme activity," <i>Science</i> , 1988, 239:1534-1536 (Abstract only)
12	Vose, J.M., "Therapeutic uses of MAbs directed against CD20" <i>Cytotherapy</i> , 2000, 2:455-461. (Abstract only)

If you wish to add additional non-patent literature document citation information please click the Add button

Add

EXAMINER SIGNATURE

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.